What is the equivalent levothyroxine (synthetic T4) dose for an adult taking a 60‑mg tablet of Armour Thyroid (desiccated thyroid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Conversion of 60 mg Armour Thyroid to Levothyroxine

A 60-mg (1-grain) tablet of Armour Thyroid is approximately equivalent to 100 µg of levothyroxine, though individual dose adjustments based on TSH monitoring after 6–8 weeks are essential because desiccated thyroid contains both T4 and T3 in a fixed 4.22:1 ratio, whereas levothyroxine monotherapy relies on endogenous T4-to-T3 conversion. 1

Understanding the Pharmacologic Difference

  • Armour Thyroid delivers both levothyroxine (T4) and liothyronine (T3) in a fixed 4.22:1 ratio, which differs from the body's usual 11:1 secretion ratio and from levothyroxine monotherapy that depends entirely on peripheral conversion of T4 to T3. 2, 1
  • Desiccated thyroid preparations cause serum T3 to rise to supranormal values during the absorption phase, often associated with palpitations, because the T3 component is rapidly absorbed. 1
  • Levothyroxine (synthetic T4) has a long half-life permitting once-daily dosing, and the extrathyroidal conversion of T4 into T3 normally provides 80% of daily T3 production, which may offer protective value during illness. 1

Standard Dose Equivalency

  • The traditional conversion is that 60 mg (1 grain) of desiccated thyroid is approximately equivalent to 100 µg of levothyroxine, though this is an approximation and individual responses vary. 3
  • The mean levothyroxine dose required to normalize serum TSH in hypothyroid patients is 1.6 µg/kg per day, which typically results in 75–100 µg/day for women and 100–150 µg/day for men. 1, 3

Monitoring After Conversion

  • Wait 4–6 weeks after initiating levothyroxine before reassessing thyroid function tests (TSH and free T4), because this is the time required to achieve steady-state levels. 4
  • Measure both TSH and free T4 to assess adequacy of replacement, with a target TSH in the reference range of 0.5–4.5 mIU/L and normal free T4. 5
  • Dose adjustments should be made in 12.5–25 µg increments based on TSH results, with repeat testing every 6–8 weeks until the target range is achieved. 5

Special Considerations for the Conversion

  • Patients switching from desiccated thyroid to levothyroxine may initially report different symptomatology because the direct T3 component is removed and they must rely entirely on T4-to-T3 conversion. 1
  • Some patients previously on desiccated thyroid may require slightly higher levothyroxine doses to achieve the same TSH suppression, because serum free T4 concentrations on levothyroxine monotherapy tend to be slightly elevated or in the upper half of the normal reference range to generate the 20% of daily T3 production that would otherwise come from the thyroid gland itself. 1
  • Once adequately treated on a stable levothyroxine dose, repeat TSH testing every 6–12 months or sooner if symptoms change. 5

Common Pitfalls to Avoid

  • Do not assume a 1:1 dose equivalency between different thyroid preparations—desiccated thyroid contains both T4 and T3, whereas levothyroxine is T4 only, requiring individual dose titration. 1
  • Avoid rechecking TSH too early (before 6–8 weeks after dose change), as steady-state levels have not yet been reached and premature adjustments may lead to inappropriate dosing. 5, 4
  • Monitor for signs of overtreatment (TSH <0.1 mIU/L), which increases risk for atrial fibrillation, osteoporosis, fractures, and cardiovascular complications, especially in elderly patients. 5
  • For patients over 70 years or with cardiac disease, start levothyroxine at a lower dose (25–50 µg/day) and titrate gradually to avoid unmasking cardiac ischemia or precipitating arrhythmias. 5

References

Research

Thyroid hormone replacement therapy.

Hormone research, 2001

Research

Levothyroxine therapy in patients with thyroid disease.

Annals of internal medicine, 1993

Guideline

Levothyroxine Distribution and Pharmacokinetics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Treatment for Elevated TSH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the equivalent dosage of levothyroxine (Synthroid) and liothyronine (Cytomel) for a patient currently taking 120 mg of desiccated thyroid (Armour Thyroid)?
Is Armor thyroid (desiccated thyroid) as effective as having no thyroid function?
Can I resume the same dose of levothyroxine (thyroid hormone replacement medication) after being off of it for a week?
What is an alternative treatment to Natural Porcine (NP) thyroid for hypothyroidism?
Will a patient who started on levothyroxin (thyroid hormone replacement medication) at a dose of 25 micrograms (mcg) and is now taking 112mcg need to continue taking it for the rest of their life?
What diagnostic tests should be performed in a woman presenting with amenorrhea?
How should benign paroxysmal positional vertigo, vestibular neuritis, and Meniere’s disease be treated?
For an adult with type 1 (or insulin‑requiring type 2) diabetes who has a post‑prandial blood glucose of 291 mg/dL two hours after a meal while using an insulin‑to‑carbohydrate ratio of 1 unit per 6 g carbohydrate, how should the carbohydrate ratio be adjusted?
How does tramadol affect renal function, particularly in patients with chronic kidney disease or impaired renal function?
What is the diagnosis and appropriate fluid management for a patient with blood urea nitrogen 29 mg/dL, serum sodium 148 mmol/L, and serum chloride 111 mmol/L indicating extracellular volume depletion?
What are the indications, dosing regimen, contraindications, common adverse effects, and monitoring recommendations for Zepbound (tirzepatide) for chronic weight management in adults with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidities?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.